Literature DB >> 33886022

MicroRNA-25 Exerts an Oncogenic Function by Regulating the Ubiquitin Ligase Fbxw7 in Hepatocellular Carcinoma.

Hatem El-Mezayen1,2, Kensuke Yamamura1, Toshihiko Yusa1, Yosuke Nakao1, Norio Uemura1, Fumimasa Kitamura1, Rumi Itoyama1, Takanobu Yamao1, Takaaki Higashi1, Hiromitsu Hayashi1, Katsunori Imai1, Akira Chikamoto1, Yo-Ichi Yamashita1, Hideo Baba3.   

Abstract

BACKGROUND: MicroRNA (miRNA) expression abnormalities are implicated in tumor progression. Previous reports have indicated that microRNA-25 (miR-25) acts as a tumor suppressor or oncogene in diverse cancers. However, its molecular mechanisms in hepatocellular carcinoma (HCC) are still unclear. F-box and WD repeat domain 7 (Fbxw7) is a critical tumor suppressor and is one of the most important deregulated proteins of the ubiquitin-proteasome system in cancer. Our objective was to elucidate the role of miR-25 and Fbxw7 in HCC and to clarify the mechanism by which Fbxw7 is regulated.
METHODS: Fbxw7 expression was estimated in 210 fixed paraffin-embedded HCC samples by immunohistochemistry, and miR-25 expression was evaluated in 142 frozen HCC tissue samples by quantitative real-time PCR. Oncogenic functions of miR-25 and its role in the regulation of Fbxw7 expression were assayed in vitro.
RESULTS: miR-25 was overexpressed in HCC tissue compared with adjacent normal tissue and significantly correlated with a poorer prognosis. Moreover, it was inversely correlated with Fbxw7 expression in HCC tissues. Furthermore, miR-25 inhibition significantly reduced the proliferation, migration, and invasion of HCC cells in vitro.
CONCLUSION: miR-25 may promote tumor progression in HCC patients by repression of Fbxw7 and could serve as a promising molecular target for HCC treatment.
© 2021. Society of Surgical Oncology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33886022     DOI: 10.1245/s10434-021-09778-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Overexpression of miR-25 is associated with progression and poor prognosis of cholangiocarcinoma.

Authors:  Haibo Liu; Lujuan Ma; Jian Wang
Journal:  Exp Ther Med       Date:  2019-08-02       Impact factor: 2.447

2.  miR-25-3p promotes glioma cell proliferation and migration by targeting FBXW7 and DKK3.

Authors:  Gang Peng; Chenxing Yang; Yi Liu; Chenfu Shen
Journal:  Exp Ther Med       Date:  2019-05-15       Impact factor: 2.447

3.  Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer.

Authors:  Moulid Hidayat; Yoichiro Mitsuishi; Fumiyuki Takahashi; Ken Tajima; Toshifumi Yae; Katsumi Miyahara; Daisuke Hayakawa; Wira Winardi; Hiroaki Ihara; Yoshika Koinuma; Aditya Wirawan; Fariz Nurwidya; Motoyasu Kato; Isao Kobayashi; Shinichi Sasaki; Kazuya Takamochi; Takuo Hayashi; Yoshiyuki Suehara; Mariko Moriyama; Hiroyuki Moriyama; Sonoko Habu; Kazuhisa Takahashi
Journal:  Bosn J Basic Med Sci       Date:  2019-11-08       Impact factor: 3.363

4.  MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7.

Authors:  Jie Xiang; Jun-Biao Hang; Jia-Ming Che; He-Cheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma.

Authors:  Kaiyi Li; Shiaw-Yih Lin; F Charles Brunicardi; Philip Seu
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

6.  miR-25 is upregulated before the occurrence of esophageal squamous cell carcinoma.

Authors:  Yaxu Jia; Heng Lu; Cheng Wang; Junjun Wang; Chenyu Zhang; Fangyu Wang; Chunni Zhang
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

7.  Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods.

Authors:  L B Kinsel; E Szabo; G L Greene; J Konrath; G S Leight; K S McCarty
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

  7 in total
  4 in total

1.  FBXO9 Mediates the Cancer-Promoting Effects of ZNF143 by Degrading FBXW7 and Facilitates Drug Resistance in Hepatocellular Carcinoma.

Authors:  Zhenyu Wang; Xiaoxia Chen; Lianer Zhou; Xinge Zhao; Chao Ge; Fangyu Zhao; Haiyang Xie; Taoyang Chen; Hua Tian; Hong Li; Jinjun Li
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 2.  Clinical significance of FBXW7 loss of function in human cancers.

Authors:  Jingyi Fan; Marcia Bellon; Mingyi Ju; Lin Zhao; Minjie Wei; Liwu Fu; Christophe Nicot
Journal:  Mol Cancer       Date:  2022-03-26       Impact factor: 27.401

3.  The diagnostic and prognostic value of the miR-17-92 cluster in hepatocellular carcinoma: A meta-analysis.

Authors:  Fang Lu; Xianghong Zhao; Zhongqiu Zhang; Mengqiu Xiong; Ying Wang; Yalan Sun; Bangshun He; Junrong Zhu
Journal:  Front Genet       Date:  2022-09-02       Impact factor: 4.772

Review 4.  Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021.

Authors:  Chunyan Zhang; Caifang Sun; Yabin Zhao; Qiwen Wang; Jianlin Guo; Bingyu Ye; Guoying Yu
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.